Pasithea Therapeutics
NASDAQ: KTTAVenice, US · Founded 2020 · Delaware corporation · 2 known investors
Find your way into Pasithea Therapeutics
90 people in our graph share verified history with the Pasithea Therapeutics team — schools, employers, funds. One of them is your warm intro.
Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
Founders & leadership
Pasithea Therapeutics was founded in 2020 by Lawrence Steinman and Tiago Reis Marques.


Investors · 2
How we know: Vivo Capital's portfolio page · funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$31.8M disclosed across 3 of 4 rounds · 2020–2025
▶$30.4MraisedDec 2021 · 21 investors · BiotechnologyRule 506(b)
- Lawrence SteinmanDirector
- Simon DumesnilDirector
- Stanley M. GlossExecutive Officer
- Emer LeahyDirector
- Tiago Andre Dos Reis MarquesExecutive Officer, Director
- Yassine BendiabdallahExecutive Officer, Director
- Offering amount
- $30.4M
- Amount sold
- $30.4M
- Sales commissions
- $2.7M
- Placement agents
- EF Hutton, division of Benchmark Investments, LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.2MraisedMar 2021 · 30 investors · Other Health CareRule 506(b)
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$250KraisedJan 2021 · 1 investors · Other Health CareRule 506(b)
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlapCompanies competing with Pasithea Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Pasithea Therapeutics do?
- Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
- Who founded Pasithea Therapeutics?
- Pasithea Therapeutics was founded by Lawrence Steinman, Tiago Reis Marques in 2020.
- Who are Pasithea Therapeutics's investors?
- Pasithea Therapeutics's investors include Vivo Capital, Janus Henderson Investors.
- How much funding has Pasithea Therapeutics raised?
- Pasithea Therapeutics has disclosed $31.8M raised across 3 of its 4 known rounds.
- Where is Pasithea Therapeutics headquartered?
- Pasithea Therapeutics is headquartered in Venice, US.




